Shocking FDA Shakeup: Vinay Prasad Out — Huge Impact For CAPR & PGEN

Описание: Shocking FDA Shakeup: Vinay Prasad Out — Huge Impact For CAPR & PGEN?

The FDA has named George Tidmarsh as Acting Director of CBER following the abrupt departure of Vinay Prasad. This leadership change could mark a shift toward more permissive regulation of gene and cell therapies. Prasad, known for his strict stance on approvals, often clashed with the “Right to Try” philosophy supported by Trump. Biotech investors are now watching closely to see how this impacts companies like Precigen and Capricor Therapeutics.

I use Interactive Brokers to buy most of the stocks I talk about. Create an account and get FREE stocks here: https://ibkr.com/referral/olivier574

Disclaimer
This video is for educational and entertainment purposes only and is not investment advice. I am purely documenting my opinions on companies that interest me. I am not a Financial Advisor and I am not your Financial Advisor. You risk losing your money by investing. Please do your own due diligence and get advice from an expert. I am human and get things wrong.

Tags
FDA news, George Tidmarsh, Vinay Prasad, Precigen PRGN-2012, Capricor Deramiocel, gene therapy stocks, biotech stocks, Elevidys FDA, FDA CBER, BLA approval, CRL FDA, Marty Makary, Right to Try, RFK FDA, FDA shakeup, FDA leadership change, FDA gene therapy, PGEN stock, CAPR stock, biotech investing, FDA news, George Tidmarsh, Vinay Prasad FDA, CBER director, FDA biologics division, PRGN-2012, Precigen, Capricor Therapeutics, Deramiocel, Elevidys, Sarepta Therapeutics, gene therapy approval, cell and gene therapy, FDA CRL, biologics license application, FDA policy shift, Right to Try law, Marty Makary FDA, biotech investing, FDA regulatory news, RFK Jr health policy, PGEN, CAPR, PGEN News, CAPR News, Precigen Stock, Capricor Stock, Capricor Therapeutics Stock, Sarepta Stock,